Tag
The deal with China’s Rona Therapeutics, worth up to about $1 billion, gives Roche a gene-silencing drug aimed at ALK7, a switch in fat cells. It is a bet on what comes after GLP-1s — and it is still early.
For stage III colon cancers with a DNA-repair defect, adding the immunotherapy to standard chemotherapy halved the risk of the cancer returning. It is the first immunotherapy combination approved for use after surgery in this setting.
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.
Sefaxersen significantly cut a key marker of kidney damage in a rare disease that has suddenly attracted a wave of new treatments — and Roche is betting a once-monthly, at-home injection can stand out.